Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 14

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 14
---
 of r isk. Befo re dec iding whether to invest in our securit ies, you should ca refully consider the risk factors we describe in this p rospectus supplement, in the accompanying p rospectus, in any related f ree writing p rospectus that we may authorize to be p rovided to you or in any report in corporated by refe rence into this p rospectus supplement, inc luding our Annual Report on Form 10-K, and all amendments thereto, for the year ended June 30, 2025, ea ch of our Quarterly Reports on Form 10-Q, and in our other subsequent filings w ith the SEC. Although we discuss key risks in those risk factor descript ions, addit ional ris ks not cur rently known to us or that we cur rently deem immaterial also may impair our busin ess. Our subsequent f ilings with the SEC may contain amended and updated discussions of significant risk s. We cannot p redict fu tu re risks or estimate the extent to which they may a ffect our finan cial performance. The occur rence of any of these r isks might cause you to lose all or part of your investment in the Common Stock.

<div align='center'>Risks Related to This Offering</div>

You may experien ce imm ediate and substantial dilution as a result of this o ffering. You may also experience future dilution as a r esult of future equity o fferings.

The offering price per share in
this offering may exceed
the net tangible book value
per share of our common stock outstanding prior to
this offering. Our historical
net tangible book value as of September 30,2025
was $(19.2) million, or approximately $(0.83)
per share of our Common Stock. Assuming that an aggregate amount
of $11,702,826 of our Common Stock is sold at an
assumed offering price of $1.31 per share, the
last reported sale price of our Common Stock on
Nasdaq on December 1, 2025, our as adjusted net tangible book value as of September 30, 2025 would have
been ($7.49) million, or approximately ($0.23) per share of our Common Stock. This
represents an immediate increase in net tangible book value of $0.59 per share of our Common
Stock to new investors